Disclosed herein are, inter alia, activators of K2P potassium channels and pharmaceutical compositions thereof, and methods comprising their use for the treatment of diseases or adverse conditions related to low TREK family protein activity.
A battery-less, wirelessly powered localization system is described. In an embodiment, a wirelessly powered localization system, includes an external Tx antenna that generates a radio frequency (RF) signal that wirelessly powers a set of one or more localizers, an external Rx antenna that receives an output from the localizers, a localizer including: an Rx antenna that receives a radio frequency (RF) signal from an external Tx antenna, a passive four-stage full-wave CMOS rectifier that generates a DC voltage using the received RF signal, a low-dropout regulator that generates a stable DC voltage based on the rectifier-generated voltage, a frequency divider circuit to divide the frequency of received RF signal, and a Tx antenna that outputs an RF signal at the divided frequency to the external Rx antenna.
A61B 5/24 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci
G01S 1/02 - Radiophares ou systèmes de balisage émettant des signaux ayant une ou des caractéristiques pouvant être détectées par des récepteurs non directionnels et définissant des directions, situations ou lignes de position déterminées par rapport aux émetteu; Récepteurs travaillant avec ces systèmes utilisant les ondes radioélectriques
3.
MINIATURE MAGNETIC SHIELDS WITH MAGNETIC THROUGH SUBSTRATE VIAS
One or more embodiments relate to custom microfabricated magnetic shields that are configured to provide isolation of superconducting electronics (SCE) circuits/chips from each other and an external environment. Whereas most superconducting circuits require magnetic shielding and most shields work by fully encapsulating the circuits, leaving little access for quite rigid and fragile fibers, one or more embodiments allow custom magnetic shield shapes to be fabricated. The shield design can depend upon the particular application, and many variations are possible. For example, in an optical interconnect application, the design can depend on whether an active (VCSEL) or passive photonic (grating/edge coupled) scheme is selected — a flexible solution is provided that supports both techniques. The shields can be created by depositing a monolithic layer conformally in a pit that has been fabricated in a silicon substrate. In embodiments, to improve the shielding, magnetic vias composed of permalloy can be introduced into the shield design. The vias can connect the magnetic shield to a permalloy layer beneath the silicon substrate.
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p.ex. loxapine, staurosporine
344 precursor powders with lower molar percentages of NaCl resulting in a composition with reduced or no-crystallinity and an increased concentration of Na vacancies.
H01M 10/05 - Accumulateurs à électrolyte non aqueux
H01M 10/056 - Accumulateurs à électrolyte non aqueux caractérisés par les matériaux utilisés comme électrolytes, p.ex. électrolytes mixtes inorganiques/organiques
H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p.ex. phosphates, silicates ou borates
6.
METHODS AND COMPOSITIONS USEFUL FOR FRACTIONATING BIOMASS USING A SCHIFF-BASE IONIC LIQUID
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (USA)
Inventeur(s)
Mohan, Mood
Choudhary, Hemant
Pidatala, Venkataramana R.
Simmons, Blake A.
Singh, Seema
Gladden, John M.
Abrégé
The present invention provides for a method to deconstruct a biomass: the method comprising: introducing a solvent comprising a Schiff-base ionic liquid (SBIL) to a biomass, such that the solvent solubilizes at least a part of the biomass to form a solubilized biomass mixture.
B01J 23/10 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe des terres rares
C08G 63/85 - Germanium, étain, plomb, arsenic, antimoine, bismuth, titane, zirconium, hafnium, vanadium, niobium, tantale ou leurs composés
B01J 21/00 - Catalyseurs contenant les éléments, les oxydes ou les hydroxydes du magnésium, du bore, de l'aluminium, du carbone, du silicium, du titane, du zirconium ou du hafnium
B01J 35/02 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides
The present invention provides methods of treating cancer using a STAT3 double-stranded, cyclic oligonucleotide decoy in combination with an immune checkpoint inhibitor.
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
Compositions and methods enhancing a patient's immune response to an immune stimulatory composition are disclosed. In certain embodiments, the method includes administering a composition comprising a PHD pathway inhibitor and a vaccine to a subject.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 39/215 - Coronaviridae, p.ex. virus de la bronchite infectieuse aviaire
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
Provided are methods and systems for measuring lung function, such as shunt and deadspace, using pulmonary gas exchange in management and treatment of pulmonary diseases including COVID-19.
Disclosed herein are DARPin backbones that form multimer and self-assembling protein cages that comprise proteins, which comprise DARPin backbones, fused to subunit proteins of the self-assembling protein cages and methods of making and using thereof.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
G01N 23/20 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p.ex. rayons X ou neutrons, non couvertes par les groupes , ou en utilisant la réflexion de la radiation par les matériaux
13.
SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS
A method of inhibiting propagation of protein misfolding associated with a neurological disease, is carried out by contacting an environment populated with a propagating amyloid conformation of a protein (prion) associated with a neurological disease with molecules which binds multiple adjacent sites of the protein assemblies and allowing the molecules to bind multiple cites of the protein assemblies; and thereby impeding propagation of the disease-associated conformation of the protein in the environment. Drug/prion complexes are formed and uses of the drugs in detection and treatment of neurodegenerative diseases are disclosed.
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
14.
FLEXIBLE DIRECTIONAL FREQUENCY MULTIPLEXING FOR MULTI-USER RF NETWORKS
An antenna device includes an antenna array having a plurality of antennas. An RF structure has a component that can vary phase response over frequency through the antenna array. A controller controls the component to create frequency-direction multi-beams from the antenna array. The antenna device can be part of an RF receiver and the RF structure can include a transmission line for each of the plurality of antennas and an RF signal connection to the transmission line for each of the plurality of antennas. The component can include a programmable delay element and a programmable phase element. The controller can set a delay of each programmable delay element and a phase each of programmable phase element in real-time to create frequency-direction multi-beams from the antenna array.
H01Q 3/36 - Dispositifs pour changer ou faire varier l'orientation ou la forme du diagramme de directivité des ondes rayonnées par une antenne ou un système d'antenne faisant varier la distribution de l’énergie à travers une ouverture rayonnante faisant varier la phase par des moyens électriques avec des déphaseurs variables
H01Q 3/40 - Dispositifs pour changer ou faire varier l'orientation ou la forme du diagramme de directivité des ondes rayonnées par une antenne ou un système d'antenne faisant varier la distribution de l’énergie à travers une ouverture rayonnante faisant varier la phase par des moyens électriques avec une matrice faisant varier l'angle de déphasage
C07D 457/00 - Composés hétérocycliques contenant des systèmes cycliques indolo [4, 3-f, g] quinoléine, p.ex. dérivés d'ergoline, de formule p.ex. acide lysergique
C07D 457/02 - Composés hétérocycliques contenant des systèmes cycliques indolo [4, 3-f, g] quinoléine, p.ex. dérivés d'ergoline, de formule p.ex. acide lysergique avec des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés en position 8
C07D 457/04 - Composés hétérocycliques contenant des systèmes cycliques indolo [4, 3-f, g] quinoléine, p.ex. dérivés d'ergoline, de formule p.ex. acide lysergique avec des atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement en position 8
16.
EXCITONICALLY COUPLED COACERVATES VIA LIQUID/LIQUID PHASE SEPARATION AND METHODS FOR MAKING THE SAME
A coacervate composition includes an aqueous solution of a salt and a conjugated polyelectrolyte, which includes: a conjugated polymer backbone having a plurality of monomers; ionic sidechains; and polar nonionic sidechains. Each of the ionic sidechains and each the polar nonionic sidechains extends from each monomer of the plurality of monomers in an alternating manner.
C08L 41/00 - Compositions contenant des homopolymères ou des copolymères de composés possédant un ou plusieurs radicaux aliphatiques non saturés, chacun ne contenant qu'une seule liaison double carbone-carbone et l'un au moins étant terminé par une liaison au sou; Compositions contenant des dérivés de tels polymères
17.
DEUTERON BREAKUP NEUTRON TARGET FOR ISOTOPE PRODUCTION
A target assembly capable of producing a neutron flux with a sufficient flux and energy distribution based on accelerator-driven thick target deuteron breakup includes a low-Z deuteron breakup target and a supporting structure in which the deuteron break-up target is located. The target may be formed, for example, from graphite, metallic beryllium, a beryllium-water combination or liquid lithium. The supporting structure may be formed from a material with a high thermal conductivity because of the high heat flux that is generated at the location of the target.
G21G 1/04 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p.ex. production d'isotopes radioactifs à l'extérieur des réacteurs nucléaires ou des accélérateurs de particules
222) includes providing a solution that contains a rare-earth element, and bubbling earth abundant nitrogen through the solution to produce atomic nitrogen (N).
Systems and methods of wirelessly powered stimulators and implantable pulse generators that can generate stimulations with programmable amplitudes and RF spectrum control in the RF domain are described. An embodiment includes an implantable pulse generator that includes: an Rx antenna configured to receive a radio frequency (RF) signal; a demodulator coupled to the Rx antenna, the rectifier, and a source, and configured to control an output of a train of mini-pulses, based on the RF signal, each mini-pulse having a voltage amplitude and a pulse width (on-portion) smaller than a pulse width TO; and stimulation circuitry 250 coupled to receive the train of minipulses and deliver the train of mini-pulse to an electrode, where the train of mini-pulses to the electrode effectively corresponds to a stimulation pulse, having a pulse width TO and an amplitude that is a function of the pulse widths of the mini-pulses.
A nanoparticle comprising a cytoplasmic type citrus leprosis virus-like particle (CiLV-C) p29 protein coat and an optional agent encapsulated with the protein coat is provided herein. The nanoparticles are useful for the delivery of the agents to cells or tissues.
The present disclosure relates to microorganisms useful in the biosynthesis of psicose. Also provided are methods of producing the disclosed microorganism and methods of producing psicose.
C12N 15/75 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p.ex. Lactobacillus, Micromonospora pour Bacillus
Compositions and methods for treating oxidative stress, and conditions where oxidative stress contributes to conditions such as diabetes, in a subject by administering an effective amount of cobinamide. Oxidative stress can be caused by, for example, increased levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in the patient. Compositions and methods for treating oxidative stress that contributes to diabetes-associated conditions such as cardiac fibrosis, and to aortic aneurysm, lipid or protein oxidation, or DNA damage, in a subject by administering an effective amount of cobinamide.
The disclosure provides, in various aspects, methods of treating cancer in a subject in need of treatment therefor, comprising administering to the subject a therapeutically effective amount of an osteoprotegerin inhibitor, wherein the osteoprotegerin inhibitor inhibits osteoprotegerin binding to TRAIL. In further aspects, the disclosure provides methods of achieving a therapeutic outcome in a subject in need of treatment, wherein the method comprises the administration to the subject of a treatment which inhibits OPG-mediated suppression of tumor immunity.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Disclosed herein are engineered peptides for treatment of diseases or conditions such as cancer. Also disclosed herein are pharmaceutical compositions containing engineered peptides of the present disclosure. Also disclosed herein are methods of treating a disease or condition by administering an engineered peptide of the present disclosure. Also disclosed herein are methods of making engineered peptides described herein.
C07K 14/435 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
C07K 7/50 - Peptides cycliques contenant au moins une liaison peptidique anormale
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
25.
BINDING AGENT RECOGNITION OF DRUG-PEPTIDE CONJUGATES
The present disclosure relates generally to antibodies reactive with drug-peptide conjugates, as well as drug-peptide-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and drug-peptide-binding fragments. The antibodies and binding fragments are useful for diagnosis and treatment of cancers that present a neoantigen formed by binding of an inhibitor to an oncoprotein.
C07K 16/44 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel non prévu ailleurs
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 51/10 - Anticorps ou immunoglobulines; Leurs fragments
inter aliainter alia, are methods of treating pain by administering compositions that include at least one purified free amino acid, at least one purified fatty acid, and a purified fatty acid amide, related compositions, and kits thereof.
A61K 31/164 - Amides, p.ex. acides hydroxamiques d'un acide carboxylique avec un aminoalcool, p.ex. céramides
A61K 31/20 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique
27.
REPROGRAMMING TROPISM VIA DISPLAYED PEPTIDES TILING RECEPTOR-LIGANDS
Methods and systems for improving the diagnosis of rare diseases using electronic health records data include training a model to estimate the presence of a disease in a subject comprising: obtaining a plurality of health records comprising health information about individuals, modifying each health record of the plurality of health records to exclude certain health information, identifying potential indicators of a disease based on publicly available databases, where the disease is a rare disease (e.g., a disease that occurs in approximately one in 100,000 individuals), and the potential indicators comprise health information present in the health records and training the machine learning model using the plurality of health records and based at least in part on the results of evaluating the accuracy of the machine learning model to recommend a referral for evaluating the presence of a disease in one or more subjects.
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p.ex. pour des dossiers électroniques de patients
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
G16H 70/60 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des pathologies
G06F 16/2458 - Types spéciaux de requêtes, p.ex. requêtes statistiques, requêtes floues ou requêtes distribuées
G06F 16/28 - Bases de données caractérisées par leurs modèles, p.ex. des modèles relationnels ou objet
29.
SYSTEM AND METHOD FOR INDEFINITE AND BIDIRECTIONAL NEAR INFRARED NANOCRYSTAL PHOTOSWITCHING
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY (République de Corée)
Inventeur(s)
Chan, Emory
Abrégé
A photo-switchable nanocrystal can be provided which can include solely one or more inorganic elements. Further, a method for synthesizing photo-switchable nanocrystal can be provided which can utilize solely inorganic elements. For example, the fully inorganic element(s) can comprise lanthanide ion (Ln3+)-based phosphors. Further, the nanocrystal can be photostable and/or does not photodegrade with light excitation cycles.
Disclosed is a magnetic prosthetic suspension system. The system includes a magnetic implant configured to be fixedly attached to bone at a target site of a subject, a socket configured to fit over the target site of the subject, and a magnet positioned on or within the socket, where the magnet is configured to generate a magnetic attractive force between the magnetic implant and the magnet that suspends the socket at the target site of the subject.
The present disclosure provides UL141 variants with one or more mutations, pharmaceutical compositions, diagnostic compositions, and kits containing the variants, nucleic acids and expression vectors encoding the variants, cells comprising the same, and methods of using the variants, nucleic acids, expression vectors, and cells for therapeutic and diagnostic purposes.
222 sensor genes and the redundant MAP kinases MPK4/MPK12, and HT1 protein kinase, and their genes. In alternative embodiments, provided are dominant active HT1 mutants that cause a high CO2-insensitive constitutively open stomatal phenotype. In alternative embodiments, the invention provides plants, and plant tissues, having increased water use efficiency, and drought-resistant plants, plant tissues and cells; and methods for engineering of water transpiration and water use efficiency in plants, and engineering plants with increased water use efficiency and drought-resistant plants, plant tissues and cells. For plants grown in humid regions with sufficient water availability, down-regulation of the CO2 sensor proteins provides plants that show less stomatal closing in light of the atmospheric CO2 increase for enabling enhanced CO2 influx into leaves.
Compositions and methods of treatment for osteoarthritis and cartilage damage in a subject comprising administering to a subject in need thereof an effective amount of a nicotinamide-riboside (NR) and pterostilbene (PT) in a ratio of about 2:1.
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
SAN JOSE STATE UNIVERSITY RESEARCH FOUNDATION (USA)
Inventeur(s)
Good, Nathan Michael Good
Martinez-Gomez, N. Cecilia
Skovran, Elizabeth
Abrégé
A microbial platform for rare earth element bioaccumulation comprises a bacterial culture, a medium comprising methanol, inorganic phosphate, and a swarf pulp, wherein the platform is selective for bioaccumulation of a rare earth element.
A particulate matter detection device takes holographic images of flowing particulate matter concentrated by a virtual impactor, which selectively slows down and guides larger particles to fly through an imaging window. The flowing particles are illuminated by a pulsed laser diode, casting their inline holograms on a CMOS image sensor in a lens-free mobile imaging device. The illumination contains three short pulses with a negligible shift of the flowing particle within one pulse and triplicate holograms of the same particle are recorded at a single frame revealing different perspectives of each particle. A deep neural network classifies the particles based on the acquired holographic images. The device was tested using different types of pollen and achieved a blind classification accuracy of 92.91%. This mobile and cost-effective device weighs ~700 g and can be used for label- free sensing and quantification of various bio-aerosols over extended periods.
G01N 15/02 - Recherche de la dimension ou de la distribution des dimensions des particules
G01N 15/14 - Recherche par des moyens électro-optiques
G03H 1/04 - Procédés ou appareils pour produire des hologrammes
G03H 1/26 - Procédés ou appareils adaptés spécialement pour produire des hologrammes multiples ou pour en obtenir des images, p.ex. procédés pour l'holographie à plusieurs couleurs
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
37.
METHOD AND APPARATUS FOR PHOTO ACOUSTIC-GUIDED ULTRASOUND TREATMENT FOR PORT WINE STAINS
Port wine birthmark, also known as port wine stain (PWS) is a skin discoloration characterized by red/purple patches caused by vascular malformation. In this disclosure, we propose a photoacoustic (PA) guided US focusing methodology for PWS treatment which combines the optical contrast- based selectivity with US penetration to focus the US energy onto the vasculature. The PA signals collected by the transducers when time-reversed and transmitted converge onto the PWS, thus, minimally affecting the neighboring tissue. We performed simulations that mimic realistic transducers and medium properties for this proof of concept study demonstrating the feasibility of the proposed methodology.
A61B 18/20 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p.ex. de micro-ondes en utilisant des lasers
38.
SYSTEMS, DEVICES AND METHODS FOR NEUROFEEDBACK TO PROMOTE BRAIN COHERENCE
Disclosed are devices, systems and methods for acquiring, analyzing, and utilizing neurofeedback to promote brain coherence. Neurofeedback is a form of biofeedback that allows an individual to regulate his/her brain activity by providing a visual metaphor of brain function, thereby making it accessible for manipulation. In some embodiments of the present technology, a system includes a brain signal detection device wearable by a subject and a computer device including a display and a brain-computer interface (BCI) configured to monitor brain signals and display visual, auditory, and/or tactile stimuli to the subject according to a neurofeedback threshold-based protocol to deliver brain signal coherence between the left and right hemispheres of a subject's brain.
Disclosed herein are optical systems and platforms for the simultaneous assessment of one or more properties of a sample, e.g., a biomolecule-containing pharmaceutical composition, including, e.g., aggregation, phase separation, and/or viscosity, as well as methods of using the same.
Acid degradable solid lipid nanoparticles comprise PEG conjugated to cholesterol via an acid degradable linkage comprising an azide-benzaldehyde acetal.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p.ex. cholane, cholestane, ergostérol, sitostérol
In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for detecting proteases including detecting proteases in a biological sample. In alternative embodiments, products of manufacture, formulations, mixtures or kits are used for stabilizing (or substantially stabilizing) nanoparticles in a reversible aggregate, and, detecting the presence of a protease in a fluid, wherein optionally the products formulations or mixtures can aggregate or assemble into nanoparticles such that the nanoparticles undergo plasmonic coupling, and the plasmonic coupling is reversible (or substantially reversible) leading to monodisperse nanoparticles when a chemical cue or signal is added.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
42.
HIGH THROUGHPUT CHARACTERIZATION OF BACTERIAL PROMOTERS FROM THEIR HOST ENVIRONMENTS
The present invention provides for methods and compositions for recovering high concentrations of transcripts is technically challenging for bacteria colonizing within the host environments. The invention uses Pi-seq technology in a DNA-barcoded promoter library to improve the ability to quantify transcriptional activity of bacterial genes. The invention offers a rapid way to screen and identify biosensors for chemicals and physical conditions associated with host physiology.
A system, apparatus and method are provided for operating a medical instrument with an automated surgical system such that the instrument starts and stops automatically depending on its location, orientation, and/or other information. Thus, instead of requiring continual supervision by a surgeon and/or other personnel, one or more functions of the instrument can be activated, paused, reactivated, or deactivated through normal manipulation of the instrument without interrupting or impeding the work flow. A volume of operation for a medical procedure may be identified manually or automatically, based on the nature of the procedure, the part of a patient's body involved in the procedure, and/or other factors. When the automated surgical system detects entry of the instrument into the volume of operation, the instrument is automatically activated and is subsequently automatically deactivated upon departure from the volume of operation.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
44.
PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED DEEP-TUMOR PENETRATION OF POLYMER NANODRUGS AND METHODS OF USE THEREOF
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
45.
DIGITAL FERROFLUIDIC DEVICE AND METHOD FOR MULTIPLEXED ASSAYS AND VIRAL TESTING
A ferrofluidic fluid assay device uses swarm of millimeter-sized magnets was employed as mobile robotic agents ("ferrobots") for precise and robust handling of magnetized sample droplets and high-fidelity delivery of flexible assay workflows. Within a palm-sized printed circuit board-based programmable platform a myriad of sample handling and bioanalytical operations involved in pooled testing can be performed. This automated technology was applied using the loop-mediated isothermal amplification and detection of SARS-CoV-2 virus in clinical samples, where the test results completely matched those obtained off-chip. This technology is easily manufacturable and distributable, and its adoption for viral testing could lead to a 10 to 300-fold reduction in reagent costs, and three orders of magnitude reduction in instrumentation cost. Multiplexed assays may also be performed on a single device.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
G01N 27/06 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un liquide
46.
PEPTIDE-LOADED ANTIGEN PRESENTING CELL-DERIVED EXTRACELLULAR BLEBS AS A MOLECULARLY TARGETED VACCINE
The disclosure provides for vaccine preparations compnsing isolated or purified extracellular blebs that display engineered MHC I and MHC II peptides that target specific antigen(s) or a specific epitope(s) from a pathogen, and uses thereof, including for vaccination against the pathogen and disease.
Provided herein are compositions and methods for determining telomere length. In some embodiments, methods include attaching a telomere tagging probe to a 3' end of the telomere to generate a tagged telomere sequence and use of a splint oligonucleotide comprising a nucleic acid sequence that specifically binds to at least a portion of the telomere tagging probe and to at least a portion of the telomere.
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
A61K 47/55 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique l’agent de modification étant aussi un agent pharmacologiquement ou thérapeutiquement actif, c. à d. le conjugué entier étant un co-médicament, p.ex. un dimère, un oligomère ou un polymère de composés pharmacologiquement ou thérapeutiquement actifs
A61K 47/66 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé l’agent de modification étant un système de pré-ciblage impliquant un peptide ou une protéine pour cibler des cellules spécifiques
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes
48.
COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF CRISPR-CAS EFFECTOR POLYPEPTIDES
The present disclosure provides enveloped delivery vehicles (EDVs) comprising a nucleic acid-binding effector polypeptide, or a nucleic acid encoding the nucleic acid-binding effector polypeptide, where the EDV comprises a fusion polypeptide comprising (i) a viral envelope protein and (ii) a targeting polypeptide that provides for binding to a target cell. The present disclosure provides methods of using an EDV of the present disclosure for delivery of, e.g., a nucleic acid-binding effector polypeptide, to a eukaryotic cell.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
49.
MODIFIED DNA BINDING PROTEINS AND METHODS OF USE THEREOF
Modified DNA-binding proteins are provided. DNA binding proteins of interest include fusion proteins having a zinc finger DNA binding polypeptide with an alpha-helix recognition domain configured to bind to a target nucleotide sequence in a target nucleic acid, and an epigenome modifying polypeptide. Aspects of the invention also include nucleic acids having a nucleotide sequence encoding a fusion protein of the disclosure, as well as recombinant expression vectors and cells including the same. The present disclosure further provides methods of silencing a target nucleic acid in a cell and/or epigenetically modifying transcription of a target nucleic acid using the subject fusion protein.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/117 - Acides nucléiques présentant des propriétés immunomodulatrices, p.ex. contenant des motifs CpG
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
Methods and systems for generating a sound. The method includes obtaining meshes representing at least one object in a frame of an environment, the environment including a source and a receiver; determining spatial continuity information and reflection normal information of the meshes; determining, based on the spatial continuity information and the reflection normal information, reflection paths between the source and the receiver involving the at least one object, each of the reflection paths having at least one reflection point associated with the at least one object; obtaining spatially sampled results by spatially sampling a space around the at least one reflection point of reflection paths using multiple distributions of rays, the spatially sampled results correlating with geometric information of the meshes; generating reflection amplitude responses for each of multiple audible frequencies in the environment based on the spatially sampled results; and producing a sound based on the reflection amplitude responses.
The present invention provides novel bioactive and biocompatible polymers derived from salicylic acid and itaconic acid. The present invention also provides hydrogels formed from these bioactive and biocompatible polymers, and methods of using such hydrogels to promote plant growth and/or to increase drought and stress tolerance.
C08G 63/06 - Polyesters dérivés soit d'acides hydroxycarboxyliques, soit d'acides polycarboxyliques et de composés polyhydroxylés dérivés des acides hydroxycarboxyliques
A01N 37/10 - Acides carboxyliques aromatiques ou araliphatiques, ou leurs thio-analogues; Leurs dérivés
52.
NEXT-GENERATION SEQUENCING PIPELINE FOR DETECTION OF ULTRASHORT SINGLE-STRANDED CELL-FREE DNA
A method of isolating ultrashort single-stranded cell-free DNA (uscfDNA) is described as well as methods of using the uscfDNA for detecting biomarkers and diagnosing diseases and disorders.
THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventeur(s)
Shipman, Seth
Lopez, Santiago C.
Abrégé
Described herein are retron-related constructs, expression systems, and methods for precisely deleting, inserting and/or replacing genomic DNA within cells. The inventors have found that CRISPR "single-cutter" methods are substantially less efficient at insertion/replacement of large fragments in comparison to the dual-cutter constructs, expression systems, and methods described herein.
A dynamic counterbalance system is provided. The dynamic counterbalance system can include a compound pulley system and an adjustment arm. The compound pulley system can include a frame, a spring, a variable radius pulley, a plurality of mounted pulleys, a plurality of moveable pulleys, and a plurality of lines. The adjustment arm can include a mountable support, a spool support, a spool, an arm inner support, a rod support, an extended rod, a rod end cap, a traveling pulley, a dynamic pulley, and a plurality of lines.
B66D 3/06 - Moufles ou dispositifs similaires dans lesquels la force est appliquée à une corde, un câble ou une chaîne qui passe sur une ou plusieurs poulies, p.ex. pour obtenir une démultiplication à plusieurs poulies
B66D 3/04 - Moufles ou dispositifs similaires dans lesquels la force est appliquée à une corde, un câble ou une chaîne qui passe sur une ou plusieurs poulies, p.ex. pour obtenir une démultiplication
A01K 15/02 - NÉCESSITÉS COURANTES DE LA VIE ÉLEVAGE; CHASSE; PIÉGEAGE; PÊCHE ÉLEVAGE; AVICULTURE; APICULTURE; PISCICULTURE; PÊCHE; OBTENTION D'ANIMAUX, NON PRÉVUE AILLEURS; NOUVELLES RACES D'ANIMAUX Équipement pour l'entraînement ou l'exercice; Cabines pour saillies Équipement pour l'entraînement ou l'exercice, p.ex. labyrinthes pour animaux
A61H 3/00 - Appareils pour aider des personnes handicapées à marcher
A63B 21/00 - Appareils de gymnastique pour développer ou fortifier les muscles ou les articulations du corps en surmontant des résistances, avec ou sans dispositifs de mesure
55.
FIBROBLAST ACTIVATION PROTEIN ALPHA-CLEAVABLE PRO-PEPTIDES AND METHODS OF USE
in vivoin vivo. In some embodiments, a pro-peptide of the present disclosure comprises a membrane interacting domain, a masking domain, and a FAPα cleavage site. The masking domain, when linked to the membrane interacting domain, is effective to inhibit interaction of the membrane interacting domain with a phospholipid bilayer. The FAPα cleavage site is disposed between the membrane interacting domain and the masking domain. The membrane interacting domain may be conjugated to one or more therapeutic agents, non-limiting examples of which include radioisotopes. Also provided are methods of treating a condition associated with FAPα expression in a subject in need thereof, such methods comprising administering an effective amount of a pro-peptide of the present disclosure to the subject.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
Disclosed are methods and compositions for inhibiting endocytosis and enhancing function of hematopoietic stem cells. Certain aspects are directed to increasing MYCT1 activity or expression to improve hematopoietic stem cell self-renewal and/or engraftment ability.
A surface-emitting, single mode laser includes a gain medium and a photonic structure. The gain medium is configured to emit an electromagnetic wave. The photonic structure is electromagnetically coupled to the gain medium and has a cavity mode-dependent scaling of losses so that higher order modes are coupled to more lossy bands and a fundamental mode, at a high symmetry point, is coupled to a less lossy band of the photonic structure.
58.
COMPOSITIONS AND METHODS FOR REDUCING IONIZING RADIATION-INDUCED HEMATOPOIETIC STEM CELL DAMAGE
The present disclosure provides methods for reducing ionizing radiation-induced damage of cells such as hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). The methods comprise introducing into HSCs and/or HPCs a fusion protein comprising (a) a zinc finger DNA binding polypeptide with an alpha-helix recognition domain configured to bind to a target nucleotide sequence in a target nucleic acid, and (b) an epigenome modifying polypeptide.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/117 - Acides nucléiques présentant des propriétés immunomodulatrices, p.ex. contenant des motifs CpG
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C07D 487/02 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient deux hétérocycles
C07D 403/10 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
61.
COMPOSITIONS AND METHODS FOR THREE-DIMENSIONAL SPATIAL BIOMOLECULE IDENTITY AND ABUNDANCE ASSESSMENT
Proper functioning of the human body relies on the organization of cells in 3D space. A cell's function and fate are determined by its biomolecule composition and 3D environment. The spatial identification of proteins, RNAs, DNAs, and other biomolecules in a tissue thus provides a powerful map to decipher how cells build tissues and become diseased. Thus, described herein are methods and compositions for assessing biomolecule identity (the present invention features methods and compositions for assessing biomolecule identity (e.g., genes (DNA, RNA), DNA and RNA modifications, proteins, protein modifications, lipids, sugars, metals), and abundance (e.g., RNA expression levels, protein translation levels) in a 3D tissue sample.
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p.ex. pour test de réaction en chaîne par polymérase [PCR]
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le ribosyle comme radical saccharide
62.
III-NITRIDE-BASED VERTICAL CAVITY SURFACE EMITTING LASER (VCSEL) WITH A DIELECTRIC P-SIDE LENS AND AN ACTIVATED TUNNEL JUNCTION
A III-nitride-based vertical cavity surface emitting laser (VCSEL) includes an active region between p-type and n-type layers; and a curved mirror on or above the p-type layer such that the p-type layer is between the active region and the curved mirror. The VCSEL includes a tunnel junction between the p-type layer and a curved mirror, wherein the tunnel junction is a planar tunnel junction and a p++-type layer of the tunnel junction is activated through sidewalls of the VCSEL. The curved mirror is formed on or above the tunnel junction, such that the tunnel junction is between the curved mirror and the p-type layer. The VCSEL further comprises a flat distributed Bragg reflector (DBR) mirror, the curved mirror comprises a curved DBR mirror, the III-nitride active region is between the flat DBR mirror and the curved DBR mirror, and the flat DBR mirror and the curved DBR mirror define a cavity of the VCSEL.
H01S 5/12 - Structure ou forme du résonateur optique le résonateur ayant une structure périodique, p.ex. dans des lasers à rétroaction répartie [lasers DFB]
H01S 5/125 - Lasers à réflecteurs de Bragg répartis [lasers DBR]
H01S 5/18 - Lasers à émission de surface [lasers SE], p.ex. comportant à la fois des cavités horizontales et verticales
H01S 5/183 - Lasers à émission de surface [lasers SE], p.ex. comportant à la fois des cavités horizontales et verticales comportant uniquement des cavités verticales, p.ex. lasers à émission de surface à cavité verticale [VCSEL]
H01S 5/187 - Lasers à émission de surface [lasers SE], p.ex. comportant à la fois des cavités horizontales et verticales comportant uniquement des cavités horizontales, p.ex. lasers à émission de surface à cavité horizontale [HCSEL] à réflexion de Bragg
H01S 5/10 - Structure ou forme du résonateur optique
H01S 5/11 - Structure ou forme du résonateur optique comprenant une structure de bande photonique interdite
H01S 5/32 - Structure ou forme de la région active; Matériaux pour la région active comprenant des jonctions PN, p.ex. hétérostructures ou doubles hétérostructures
H01S 5/34 - Structure ou forme de la région active; Matériaux pour la région active comprenant des structures à puits quantiques ou à superréseaux, p.ex. lasers à puits quantique unique [SQW], lasers à plusieurs puits quantiques [MQW] ou lasers à hétérostructure de confinement séparée ayant un indice progressif [GRINSCH]
63.
CHROMOSOME 9P24 LOSS AND GAIN PREDICTS RESISTANCE AND BENEFIT OF IMMUNE CHECKPOINT INHIBITORS
The disclosure further provides diagnostic, prognostic, and therapeutic methods, which are based, at least in part, on determination of the identity of a genotype of interest identified herein.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
64.
ALLEVIATING GRAFT VERSUS HOST DISEASE USING ENGINEERED INKT CELLS
We have discovered that allogeneic HSC-engineered human iNKT (3rdin vitroin vitro and in xenograft models, without negatively impacting tumor eradication by allogeneic T cells in preclinical models of lymphoma and leukemia. The 3rdHSC-iNKT cells closely resembled the CD4-CD8-/+ subsets of endogenous human iNKT cells in phenotype and functionality. Embodiments of the invention harness these discoveries in new methods and materials for alleviating graft versus host disease.
Antibodies, including single-domain antibodies, that bind to SARS-CoV2 virus and methods of treatment using single-domain antibodies that bind to SARS-CoV2 virus are provided.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
The present disclosure generally relates to multi-chain chimeric polypeptides or receptors having distinct polypeptide chains that associate post-translationally to enable the simultaneous activation of the signaling domain and the release of a transcriptional regulator upon binding of a ligand. The disclosure also provides nucleic acid constructs, recombinant cells, vectors, pharmaceutical compositions, and methods of treatment including the multi-chain chimeric polypeptides of the disclosure. The disclosure further provides methods for simultaneously inducing T cell signaling and gene regulation in a T cell.
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
68.
APODIZATION SPECIFIC FITTING FOR IMPROVED RESOLUTION, CHARGE MEASUREMENT AND DATA ANALYSIS SPEED IN CHARGE DETECTION MASS SPECTROMETRY
A method for Charge Detection Mass Spectrometry (CDMS) with improved accuracy with reduced computation requirements. An apodization-specific peak fitting function is used to determine peak amplitudes and frequencies in the Fourier transform of ion signals to measure the charge and mass of an individual ion in charge detection mass spectrometry. Up to approximately 28% or more amplitude measurement precision is achieved when compared to conventional peak picking methods. About a 9-fold less computational effort is required to achieve the same accuracy of determining peak amplitude and frequency as the standard method of zero fill-based interpolation.
Blood loss (hemorrhage) accounts for one third of about 5 million trauma fatalities worldwide every year. We have developed the first-of-a-kind microneedle arrays (MNAs) that are able to reduce the blood clotting time by a factor of 1200 % compared to untreated blood. Photocrosslinkable gelatin (gelatin methacryloyl, GelMA) was nanoengineered using silicate nanoplatelets (SNs) and casted as MNAs. The SNs rendered the MNAs hemostatic while microneedles increased the contact area of biomaterials with blood, synergistically accelerating the clotting process. Hemostatic MNAs significantly outperformed the hemostatic effect of nanoengineered GelMA hydrogels and plain (needleless) patches via combining both micro- and nanoengineered material features. Such biodegradable hemostatic MNAs pave the way towards rapid hemorrhage control, particularly in remote places with limited or no immediate access to hospital.
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
70.
NOVEL RECEPTORS WITH SYNTHETIC TRANSMEMBRANE DOMAINS FOR ENHANCED CONTROL OF LIGAND-DEPENDENT TRANSCRIPTIONAL ACTIVATION
The present disclosure relates generally to the manipulation of chimeric polypeptide signaling to decrease cancer cell proliferation, and particularly to a new class of receptors engineered to (i) bind a target cell-surface displayed ligand and (ii) have a synthetic transmembrane domain. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various diseases such as cancers.
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
71.
STRUCTURE-BASED DESIGN OF A NOVEL CLASS OF DRUGS FOR NEURODEGENERATIVE DISEASE
The invention provides pharmaceutical compositions comprising molecules capable of disassembling tau amyloid fibrils or alpha-synuclein amyloid fibrils, as well as methods for making compositions comprising these molecules. Embodiments of the invention also include methods for using these molecules to facilitate the disassembling of tau amyloid fibrils or alpha-synuclein amyloid fibrils.
The present disclosure relates generally to methods and systems of producing Schwann cells from pluripotent stem cells under fully defined conditions. The Schwann cells produced by the disclosed methods find applications as models of the enteric nervous system, tools for highthroughput screening of potential therapeutics for treatment of enteric neuropathies, and in regenerative medicine.
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
73.
IMPROVED GLYCEMIC CONTROL BY ADMINISTRATION OF MICRO-RNA 192
The disclosure provides, in various aspects, methods of achieving a selected therapeutic outcome in a subject by administration to the subject of a therapeutically effective amount of an miR-192 agent. In further aspects, the disclosure provides methods of assessing an enhanced risk of statin-induced new onset diabetes (NOD) in a subject, as well as kits comprising elements to perform methods of the disclosure.
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
The present embodiments include a biomaterial with immunomodulating properties engineered for complete incorporation into injured tissues while enhancing the regenerative healing activities of immune and stromal cells. The biomaterial may be used in, but not limited to, skin or muscle. A first component in some embodiments is gelatin or gelatin methacryloyl. In the present embodiments, this component consists of a specific composition and its modification with another therapeutic component. A second component of some embodiments, apoptotic neutrophil cells, has not previously been used in biomaterials for wound healing nor in combination with the first gelatin-based component.
A61K 35/17 - Lymphocytes; Lymphocytes B; Lymphocytes T; Cellules tueuses naturelles; Lymphocytes activés par un interféron ou une cytokine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol o
75.
COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER
Provided herein, inter alia, are compositions and methods comprising combination therapies including a BRAE axis inhibitor and a COX-2 inhibitor for the treatment of cancer. In embodiments, the combination therapies further include an EGER inhibitor. The combination therapies provided herein are particularly effective for treating BRAE intrinsically resistant cancers.
A wireless backscatter fiducial tag includes a Van-Atta array having a plurality of antenna patches connected by a plurality of transmission lines. A signal control device controls transmissions from the Van-Atta array. A controller provides an identification signature of the tag to the signal control device. The identification signature defines a code. The signal control device can be RF switches. The identification signature can be a spreading code configured to be orthogonal to codes of other backscatter fiducial tags being used in a system with the backscatter fiducial tag. The controller can consist of fixed shift register outputting a repeating sequence of Gold code bits as the identification signature.
G06K 7/00 - Méthodes ou dispositions pour la lecture de supports d'enregistrement
G06K 7/01 - Méthodes ou dispositions pour la lecture de supports d'enregistrement - Détails
G06K 19/07 - Supports d'enregistrement avec des marques conductrices, des circuits imprimés ou des éléments de circuit à semi-conducteurs, p.ex. cartes d'identité ou cartes de crédit avec des puces à circuit intégré
G06K 7/10 - Méthodes ou dispositions pour la lecture de supports d'enregistrement par radiation corpusculaire
The present disclosure provides antigen-binding proteins which bind to Claudin-6 (CLDN6). In various aspects, the antigen-binding proteins bind to cytoplasmic domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of detecting and quantifying Claudin-6 (CLDN6) in samples from a subject and treating a subject having cancer.
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
Provided are methods of assessing whether a subject had a stroke and treating the subject accordingly. The methods include recording electroencephalography (EEG) data from electrodes positioned on the head of the subject. Afterwards, the electrical activity from a certain location on the subject's head is compared to the electrical activity at its contralateral location and to electrical activity measured at all electrodes. These relative electrical activities are used to determine the probability that a stroke occurred in a particular part of the brain, and the subject is treated accordingly.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
A61B 5/25 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet
A61B 5/291 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG]
A61B 5/384 - Appareils d’enregistrement ou d’affichage spécialement adaptés à cet effet
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
79.
INSULIN SENSITIZERS FOR REVERSAL OF INSULIN RESISTANCE
This disclosure provides an isolated recombinant peptide comprising one or more of the FBP1 E1-E7 fragment or an equivalent thereof and a cell penetrating peptide, compositions and methods of using same to reverse insulin resistance in a subject in need thereof.
The present invention provide methods of inhibiting ATP hydrolysis using epicatechin or pharmaceutical compositions thereof. Methods of preventing Electron Transport Chain (ETC) complex V dissociation into monomers and decreasing ATP hydrolysis using epticatechin or pharmaceutical compositions thereof are also provided.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
This disclosure relates to novel lithium ion battery structures and methods of manufacture. One particular method includes a method of coating a porous glass substrate. The method includes: providing a porous glass substrate; flowing gaseous hydrocarbon onto a porous glass substrate in a reaction zone; and exposing the porous glass substrate to a concentrated solar irradiation in the reaction zone such that the porous substrate and gases surrounding the porous substrate absorb the concentrated solar irradiation producing heat. The heat chemically reduces glass fibers in the porous glass substrate into silicon fibers, and the heat decomposes the gaseous hydrocarbon into a carbon coating on the silicon fibers.
B05D 3/06 - Traitement préalable des surfaces sur lesquelles des liquides ou d'autres matériaux fluides doivent être appliqués; Traitement ultérieur des revêtements appliqués, p.ex. traitement intermédiaire d'un revêtement déjà appliqué, pour préparer les applications ultérieures de liquides ou d'autres matériaux fluides par exposition à des rayonnements
The present invention relates to novel pore monomer conjugates, pore complexes formed from the conjugates and their uses in analyte detection and characterisation.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p.ex. génie protéique ou administration de médicaments
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p.ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
C07K 14/475 - Facteurs de croissance; Régulateurs de croissance
Aspects of the disclosure relate to protein pore complexes and their uses in analyte detection and characterisation. The disclosure is based, in part, on nanopore complexes formed by CsgG-like pores and one or more auxiliary proteins, which form one or more channel constrictions in the nanopore complex. In some embodiments, the one or more auxiliary protein is a fusion protein. The disclosure further relates to methods for design of auxiliary proteins and production of the nanopore complexes, and for use in molecular sensing and analyte sequencing applications.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p.ex. génie protéique ou administration de médicaments
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p.ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
C07K 14/475 - Facteurs de croissance; Régulateurs de croissance
Shear-thinning hydrogels are suitable biomaterials for catheter-based minimally invasive therapies; however, the tradeoff between injectability and mechanical integrity has limited their applications, particularly at high external shear stress such as endovascular procedures. The invention provides an easily injectable, non-hemolytic, and non-cytotoxic shear-thinning hydrogel with significantly enhanced cohesion via controlling noncovalent interactions.
Imagining using reflected illuminated structures ("IRIS") in accordance with embodiments of the invention are disclosed. In one embodiment, an IRIS device is provided, the IRIS device comprising: a projector; a camera; a processor operatively connected to the projector and the camera; and a memory storing instructions that, when executed by the processor, cause the image capture device to: project, using the projector, a plurality of illuminated structures onto an object having an optically transparent, translucent, or opaque surface; and capture, using the camera, image data comprising a reflection of the plurality of illuminated structures from the optically transparent, translucent, or opaque surface of the object.
G06F 3/03 - Dispositions pour convertir sous forme codée la position ou le déplacement d'un élément
G03B 21/14 - Projecteurs ou visionneuses du type par projection; Leurs accessoires - Détails
G06V 10/12 - Acquisition d’images - Détails des dispositions d’acquisition; Leurs détails structurels
H04N 9/31 - Dispositifs de projection pour la présentation d'images en couleurs
G01B 11/25 - Dispositions pour la mesure caractérisées par l'utilisation de techniques optiques pour mesurer des contours ou des courbes en projetant un motif, p.ex. des franges de moiré, sur l'objet
G03B 21/00 - Projecteurs ou visionneuses du type par projection; Leurs accessoires
G02F 1/1335 - Association structurelle de cellules avec des dispositifs optiques, p.ex. des polariseurs ou des réflecteurs
G09G 3/36 - Dispositions ou circuits de commande présentant un intérêt uniquement pour l'affichage utilisant des moyens de visualisation autres que les tubes à rayons cathodiques pour la présentation d'un ensemble de plusieurs caractères, p.ex. d'une page, en composant l'ensemble par combinaison d'éléments individuels disposés en matrice en commandant la lumière provenant d'une source indépendante utilisant des cristaux liquides
86.
TRANSCRANIAL ELECTRICAL STIMULATION IN STROKE EARLY AFTER ONSET
Disclosed is a non-invasive system and related methods to deliver electrical current to ischemic brain tissue rapidly with minimal set up, to treat acute ischemic stroke via direct cytoprotection and by collateral blood flow enhancement promoting recanalization of occluded vessel. In one embodiment, the system includes a cap with plurality of electrodes which are operable in combination to deliver an electrical current when in contact onto skin of the head region of the subject. In one embodiment, the electrical current delivery is individualized to target each individual's ischemic tissue only. In one embodiment, the electrode positioning can be selected from pre-determined electrode montages according to the location of the ischemia and vessel occlusion site. In one embodiment, the system can be applied as a standalone treatment or adjunct to reperfusion therapies to salvage the at-risk ischemic tissue (aka penumbra) and improve patient outcomes.
The present disclosure provides compositions comprising a microgel scaffold formed by polyethylene glycol-vinyl sulfone (PEG-VS) and polyethylene glycol-dithiol (PEG-DT), as well as methods of making thereof.
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
Disclosed are compositions comprising a ligandable tag, a linker, and a labeling enzyme, wherein the linker attaches the ligandable tag to the labeling enzyme. Disclosed are nucleic acid sequences capable of encoding one or more of the disclosed protein based compositions. Disclosed are compositions comprising a ligand conjugated to a molecule of interest. Disclosed are systems comprising a labeling composition and a targeting composition, wherein the labeling composition comprises a ligandable tag, a linker, and a labeling enzyme, wherein the linker attaches the ligandable tag to the labeling enzyme, wherein the targeting composition comprises a ligand conjugated to a molecule of interest, wherein the ligand of the targeting composition is a ligand for the ligandable tag of the labeling composition. Disclosed are methods of using the disclosed compositions and systems.
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
The disclosure provides host cells engineered to express non-naturally occurring polyketide synthases that produce b-keto-d-lactones (BKDLs); methods of generating such host cells, and methods of producing BKDLs employing the host cells.
C07H 17/08 - Hétérocycles d'au moins huit chaînons, p.ex. érythromycines
C12P 1/04 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymes; Procédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes utilisant des bactéries
C12P 17/06 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'oxygène comme unique hétéro-atome du cycle contenant un hétérocycle à six chaînons, p.ex. fluorescéine
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (USA)
Inventeur(s)
Dou, Chang
Choudhary, Hemant
Sun, Ning
Simmons, Blake A.
Abrégé
A method for depolymerizing a mixture of plastics is described. The method comprises (a) providing a composition comprising two of more plastics, (b) introducing a solvent comprising an ionic liquid (IL) or deep eutectic solvents (DES) and optionally water to the composition to form a solvent-plastic composition, such as an aqueous solvent-plastic composition, and (c) incubating the solvent-plastic composition for a period of time to produce a depolymerized composition such that at least portions of the two of more plastics are depolymerized into monomers. The produced monomers can be used as a carbon source for microbes to produce bioproducts.
B09B 3/60 - Traitement biochimique, p.ex. en utilisant des enzymes
B01J 31/02 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques
C08J 11/28 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p.ex. dévulcanisation par traitement avec une substance organique par traitement avec des composés organiques contenant de l'azote, du soufre ou du phosphore
B09B 3/40 - Destruction de déchets solides ou transformation de déchets solides en quelque chose d'utile ou d'inoffensif impliquant un traitement thermique, p.ex. évaporation
Systems and methods of non-contact force sensing are described. An embodiment includes a non-contact force sensing system, that includes: a laser source that illuminates a surface with a laser; a camera that captures video that includes several images of the surface; a process that includes: analyzing the images of the video to determine laser speckle motion due to surface deformations to the surface; and determining an applied force on the surface based on the analysis.
G01L 1/24 - Mesure des forces ou des contraintes, en général en mesurant les variations des propriétés optiques du matériau quand il est soumis à une contrainte, p.ex. par l'analyse des contraintes par photo-élasticité
G06V 20/00 - RECONNAISSANCE OU COMPRÉHENSION D’IMAGES OU DE VIDÉOS Éléments spécifiques à la scène
92.
SELF-POWERED BIOELECTRONIC STENT SENSOR SYSTEM, DEVICE AND METHOD
A bioelectronic stent sensor system comprises a bioelectronic stent sensor device comprising a first hollow cylindrical lattice, and a second hollow cylindrical lattice attached to a first surface of the first lattice, comprising a biocompatible magnetoelastic micromesh (BMM), and a computing system communicatively connected to the bioelectronic stent sensor device, comprising a processor and a non-transitory computer-readable medium with instructions stored thereon, which when executed by a processor, perform steps comprising receiving readout current signals from the bioelectronic stent sensor device, and calculating a blood flow rate based on the readout current signals by establishing an empirical relationship between the readout current signals and a flow rate value. Related devices and methods are also disclosed.
. . In one aspect, the method includes a step of administering an effective dose of a FOXG1-AS antisense or inhibitory nucleic acid to a subject in need thereof, thereby rescuing the defects associated with altered FOXG1 expression.
The present disclosure provides methods for treating metabolic disorders. The methods generally involve administering to an individual in need thereof an effective amount of a compound of Formula I.
A61K 31/335 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine
A61K 31/34 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide
A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide non condensés avec un autre cycle, p.ex. ranitidine, furosémide, bufétolol, muscarine
Provided are improved methods for gene delivery to plants comprising injecting a polynucleotide, nucleoprotein complex, nanoparticle or plant viral nanoparticle into a stem or a petiole of the plant, thereby in it into the vascular system of the plant.
Platinum-thioester complexes, compositions comprising such platinum-thioester complexes, methods of treating cyanide poisoning and/or cyanide exposure with the same and related combinations therapies and kits therefore.
in silicoin silico perturbation" Variational Autoencoder (VAE)-based deep learning framework. Such a framework can predict alterations in gene expression profiles caused by perturbations of transcription factor (TF) expression profiles. Perturbation strategies can be used to change a cell from one state to another state, e.g., one cell type to another cell type.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
The disclosure provides devices, methods and systems for continuous dielectrophoresis cell sorting to isolate different populations of cells, and applications thereof.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
A system is configured to pick up produce. A produce sweeper assembly include a sweeper blade positioned at an adjustable height relative to a ground surface. A produce pickup assembly picks up gathered produce and includes at least one bristle that pushes the gathered produce onto a conveyor belt, which transfers the gathered produce into a produce storage assembly. A control system controls at least one aspect of the produce sweeper assembly and at least one aspect of the produce pickup assembly.